ProCE Banner Activity

How I Manage Laboratory Assay Interference With Anti-CD38 Antibodies in Myeloma

Clinical Thought
Anti-CD38 antibodies like daratumumab can cause false-positive results on blood tests in myeloma. Do you know how to mitigate this risk?

Released: October 17, 2016

Expiration: October 16, 2017

No longer available for credit.

Share

Faculty

Donna Catamero

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Oncology

Faculty Disclosure

Primary Author

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Donna Catamero, ANP-BC, OCN, CCRC, has disclosed that she has received consulting fess from Celgene and Takeda and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Amgen, Celgene, Janssen, and Takeda.